EMA Authorised: Tyverb (lapatinib) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency has authorised Tyverb (lapatinib) for breast neoplasms. The marketing authorisation holder is Novartis Europharm Limited, with a d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Tyverb (lapatinib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Novartis Europharm Limited. Decision date: 05/01/2026